AGAlica Goldman

Alica Goldman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alica Goldman has a total of 296 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Education Research: Development of a Workplace-Based Assessment to Enhance EEG Interpretation Skills for Medical Students

    by Hannah Kostan, Adam Dickey, Kareem Gadelmola, Alica M. Goldman, Vaishnav Krishnan, Lu Lin, Gabriela Tantillo, Atul Maheshwari

    Background and ObjectivesElectroencephalography (EEG) interpretation is a core competency in neurology residency training, yet structured EEG education for interested medical students remains limit...


  • Open Access

    Neuroimmunology of Epilepsy: Mechanisms, Treatments, and Clinical Insights

    by Alica M. Goldman, Nora Wong, Annamaria Vezzani, Krista Eschbach, Khalil Husari, Divyanshu Dubey, Anteneh M. Feyissa, Teneille Gofton, Ignacio Valencia

    Immune-mediated epilepsies represent an etiologically unique category defined by immune activation within the central nervous system that initiates a pathophysiological cascade resulting in seizures, encephalopathy, and sometimes epileptogenesis with long-term epilepsy. Once considered rare and largely confined to paraneoplastic or postinfectious syndromes, immune-mediated and inflammatory mechanisms are now recognized across a broad spectrum ranging from acute autoimmune encephalitis with reversible seizures, new-onset refractory status epilepticus, or febrile illness-related refractory status epilepticus, to chronic autoimmune-associated epilepsy and drug-refractory structural epilepsies. This review integrates historical perspectives, mechanistic insights from animal and human studies, and contemporary clinical frameworks. It synthesizes advances in neuroimmunology, clinical phenotyping, diagnostics, immunomodulatory and antiseizure therapies, neuromodulation, and patient and family centered outcomes, and outlines future directions focused on biomarker-driven precision medicine, disease-modifying strategies, and interdisciplinary care models.

  • Open Access

    Responsive stimulation of the thalamus for idiopathic generalized epilepsy: Results of the randomized controlled NAUTILUS trial through 18 months

    by Utku Uysal, Patrick Landazuri, David E. Burdette, Sanjay Patra, Angela N. Crudele, Dario J Englot, Jay R. Gavvala, Nitin Tandon, Sandipan Pati, Lesley C. Kaye, et al.

    Objective: This study was undertaken to evaluate the safety and effectiveness of responsive thalamic stimulation as adjunctive therapy for drug‐resistant idiopathic generalized epilepsy (IGE) with generalized tonic–clonic seizures (GTCSs). Methods: NAUTILUS is a prospective, multicenter, single‐blind, randomized sham‐controlled pivotal trial. Patients were ≥12 years of age with drug‐resistant IGE and ≥2 GTCSs over a 3‐month baseline. Bilateral depth leads were targeted to the centromedian thalamus. One month later, patients were randomized to Active (responsive stimulation, n = 44) or Sham (no stimulation, n = 43). The effectiveness evaluation period (EEP) began 3 months postimplant through 1 year. After a second GTCS in the EEP, patients transitioned to open‐label active stimulation. The primary safety endpoint was the serious adverse device‐related event (SADE) rate at 84 days postimplant. The primary effectiveness endpoint was time‐to‐second‐GTCS during the EEP. Additional endpoints included median percent change in days with any generalized seizure, GTCS frequency, and responder rate (RR). Results: Eighty‐seven patients were implanted across 23 US centers. The SADE rate was significantly below the performance goal (6.9%, p < .0001), with no adverse effects on cognition, mood, or sleep. The prespecified primary effectiveness endpoint was not significant. However, a post hoc mixed‐effects model considering all EEP days demonstrated greater GTCS reduction in the originally randomized Active group (61%) compared to patients originally randomized to Sham (49%, p = .030). Eighteen‐month outcomes included 76.8% median GTCS reduction, 62.5% RR, 40% GTCS‐free at that timepoint, and 77.8% median reduction in days with any generalized seizure. More than 90% of patients and 86% of physicians reported improvement on Global Impression of Change scales. Significance: NAUTILUS is the first randomized controlled neuromodulation trial in IGE. Responsive thalamic stimulation provided a clinically meaningful and durable reduction in seizures with an acceptable safety profile, offering a much‐needed option for drug‐resistant IGE.


  • Open Access

    A nonlinear relationship of evoked responses following charge-balanced single-pulse electrical stimulation with varying pulse widths

    by Isabel A. Danstrom, Joshua A. Adkinson, Zoe Liu, Meghan E. Robinson, Denise Oswalt, Garrett P. Banks, Atul Maheshwari, Lu Lin, Ben Shofty, Mohammed Hasen, et al.


  • The path to post-traumatic epilepsy: A review of emerging biomarkers and therapeutic targets

    by Soheil M. Yazdi, Andres Jimenez- Gomez, Alica Goldman, Spyridoula Tsetsou


  • Open Access

    Neural signatures and personalized neuromodulation in a subject experiencing context-dependent inhibitory control deficits

    by Layth S. Mattar, Shraddha Shah, Lily S. Chamakura, Denise Oswalt, Yue Zhang, Davin Devara, Jung Uk Kang, Zahra Jourahmad, Ryan Jafri, Geoffrey Liu, et al.


  • Open Access

    Neural signatures and personalized neuromodulation in a subject experiencing context-dependent inhibitory control deficits

    by Layth S. Mattar, Shraddha Shah, Lily S. Chamakura, Denise Oswalt, Yue Zhang, Davin Devara, Jung Uk Kang, Zahra Jourahmad, Ryan Jafri, Geoffrey Liu, et al.

    The ability to override prepotent actions is critical to control impulses and adjust behavior depending on goals and contextual needs. In this study, we investigate the inhibitory control abilities of a patient diagnosed with Klüver-Bucy Syndrome following a left temporal resection. The patient presented with disruptive hypersexuality symptoms akin to compulsions, leading to the inability to control and suppress inappropriate actions. The patient was recruited for the current research study while undergoing intracranial monitoring for epilepsy, to investigate the cognitive and neural processes underlying the patient’s inhibitory control symptoms. We formulated the hypothesis that an inhibitory control deficit emerges in response to provocative triggers, and we designed a personalized paradigm pairing arousing images with a classic inhibitory control task. We not only confirmed disrupted performance following exposure to triggering, provocative material, but we also leveraged the simultaneously recorded neural data to identify a biomarker reflecting inhibitory control failures. Next, we repeated the experimental paradigm during and after personalized neuromodulation via direct high-frequency stimulation of the right inferior frontal cortex. The patient displayed a marked improvement in his behavior during neuromodulation, mirrored by changes in neural activity, spanning spectral features, event-related potentials and functional connectivity. Altogether, our study revealed that the patient’s symptoms were not due to a global inhibition deficit, but to a specific control issue triggered by exposure to provocative material. Overall, our work showcases a feasible, effective approach towards data-driven personalized neuromodulation, which could be leveraged to mitigate specific inhibitory control deficits and potentially other symptoms of executive dysfunction. Abstract Figure: Graphical abstract. This case study investigates context-dependent inhibitory control abilities in a patient with Kluver-Bucy syndrome during intracranial monitoring for epilepsy .


  • Open Access

    Epilepsy Therapies Symposium | Do We Really “Outgrow” Seizures?

    by Adam Ostendorf, Genna J. Waldman, Lara Jehi, Mohammed Ilyas, Dean Naritoku, Alica M. Goldman

    Initiation and maintenance of antiseizure therapy can be relatively straightforward in most patients. Depending on epilepsy type, patients may be more or less likely to enter remission or a resolution of their epilepsy and the International League Against Epilepsy developed clinically guiding definitions in this regard. The mechanisms by which resolution or remission are achieved are poorly understood which complicates clinical decision making and risk estimate for future seizure relapse. The impetus for the maintenance of medical therapy in a seizure-free patient is also age-dependent. In children, one ought to consider the unknown effects of antiseizure medications on the developing brain while family planning, lifestyle, education, or employment are some of the issues that affect the decision making in adults. Patients who enter remission following surgical remediation of their epilepsy represent a distinct category and medication discontinuation is influenced by a number of factors. Another important consideration is comorbidities that often affect medication choices and maintenance. When formulating a management strategy, patient preferences together with careful evaluation and precise and accurate epilepsy diagnosis are key towards guiding medical or surgical management, prognostication for seizure freedom, relapse risk, options for medication discontinuation, and understanding risks and types of comorbidities.

  • The Fundamentals of Antiseizure Medications: A Through Z

    by Timothy E. Welty, Jeannine M. Conway, Jacquelyn Bainbridge, Kristen Park, David G. Vossler, Archana A. Patel, Alica Goldman

    Since bromides were first used in 1857 to treat epilepsy, numerous antiseizure medications (ASM) have been developed. Many of these are available for the treatment of epilepsy and status epilepticus today. With so many ASM available, questions arise as to whether all of these medications are needed and when should they be used. As precision medicine begins to play a larger role in determining targeted treatments for specific types of epilepsy, a complete understanding of various medications is needed. Additionally, access to several of these medications can be limited in the United States and are especially limited globally. All these factors can make proper selection of ASM challenging and difficult for clinicians. This review highlights important aspects of older and newer medications, developments in precision medicine for epilepsy, increasing understanding of effective treatments for status epileptics, and a global perspective on ASM availability.

  • Open Access

    Prophecy or empiricism? Clinical value of predicting versus determining genetic variant functions

    by Andreas Brunklaus, Alfred L. George, Dennis Lal, Erin L. Heinzen, Alica M. Goldman

    The recent explosion of epilepsy genetic testing has created challenges for interpretation of gene variants. Assessments of the functional consequences of genetic variants either by predictive or experimental strategies can contribute to estimating pathogenicity, but there is no consensus on which approach is best. The Special Interest Group on Epilepsy Genetics hosted a session during the Annual American Epilepsy Society Meeting in December 2022 to discuss this topic. The session featured a debate of the relative advantages and limitations of predicting (prophecy) versus experimentally determining (empiricism) variant function using ion channel gene variants as examples. This commentary summarizes these discussions.